By The TENS Magazine Editorial Staff
Boston-based biotechnology firm Life Biosciences has officially closed a fully subscribed $80 million Series D financing round. The capital injection is earmarked to advance the company’s pioneering Phase 1 clinical trial for its lead therapeutic candidate, ER-100. This experimental treatment is designed to address severe age-related eye diseases through a novel mechanism known as Partial Epigenetic Reprogramming (PER). The financial milestone marks a significant transition for the company as it moves from preclinical longevity research into human clinical testing.
The Series D funding round ensures that Life Biosciences is capitalized to sustain its operations into the second half of 2027. According to the company, the newly acquired funds will directly support the completion of early clinical milestones for ER-100, while also facilitating the expansion of its broader research pipeline. With this latest financial backing, the total capital raised by the firm now approaches $240 million, following an $82 million Series C in January 2022 and a $50 million Series B in 2019.
Jerry McLaughlin, Chief Executive Officer of Life Biosciences, stated that the strong participation in the financing round reflects growing investor confidence in the company’s platform. According to McLaughlin, the financial support positions the organization to deliver disease-modifying solutions for patients suffering from conditions driven by the biological aging process.
At the core of the company’s scientific approach is the Partial Epigenetic Reprogramming (PER) platform. Co-founded by Harvard University biologist David Sinclair, Life Biosciences operates on the premise that aging is a modifiable biological process. The company’s technology aims to restore aged or damaged cells to a more youthful and functional state by altering the epigenome—the chemical markers that regulate gene expression—without changing the underlying DNA sequence.
To achieve this, ER-100 utilizes an adeno-associated virus (AAV2) vector to deliver genetic instructions for three specific transcription factors: OCT4, SOX2, and KLF4. Collectively referred to as OSK, these proteins are a subset of the well-known Yamanaka factors. Unlike full cellular reprogramming, which reverts cells entirely into pluripotent stem cells and carries a significant risk of cancer, the partial reprogramming strategy employed by Life Biosciences is designed to reset epigenetic markers while carefully preserving the original identity and function of the cell.
The initial proving ground for this technology is ophthalmology. The Phase 1 clinical trial (NCT07290244) will evaluate the safety and tolerability of ER-100 in patients diagnosed with open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION). Both of these optic neuropathies are characterized by progressive damage to retinal ganglion cells (RGCs). These specialized neurons form the optic nerve, serving as the critical connection between the eye and the brain.
Because retinal ganglion cells lack the natural ability to regenerate once damaged, conditions like OAG and NAION typically lead to permanent vision impairment. Current standard-of-care treatments primarily focus on managing symptoms and slowing disease progression, rather than repairing the underlying neuronal degeneration. Life Biosciences intends for ER-100 to act as a disease-modifying therapy capable of directly protecting or regenerating these vital cells to preserve or restore sight.
Safety remains the primary endpoint for the early-stage human trials. To mitigate potential risks associated with genetic reprogramming, researchers have incorporated a secondary AAV2 vector that functions as a molecular safety switch. This mechanism allows physicians to control the expression of the reprogramming genes using an oral medication. According to preclinical data, the therapy activates when the patient takes the medication and ceases expression when the pill is discontinued, providing a crucial layer of clinical control.
While the immediate focus remains on visual function and optic neuropathies, the long-term strategy for Life Biosciences extends significantly further. The company is strategically broadening its therapeutic pipeline to address additional age-related diseases across various organs and systems. Preclinical studies have already begun exploring the application of the PER platform in other areas, including neurodegenerative conditions and hepatic diseases such as fatty liver disease.
By targeting the root epigenetic causes of cellular decline, Life Biosciences is testing a fundamental hypothesis in modern biotechnology: that reversing the biological clock of individual cells can effectively treat chronic illnesses. As the Phase 1 clinical trial progresses, the medical and investment communities will closely monitor the safety data and exploratory efficacy measures to determine the viability of partial epigenetic reprogramming as a new class of human therapeutics.
